Researchers identify deletions in the N-terminal domain of the spike protein that allow the coronavirus to avoid antibody neutralization and that may contribute to the emergence of new variants.
An additional mutation in the spike protein of the coronavirus may help it elude antibody recognition, and scientists are investigating if current vaccines will protect against it.
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.
Researchers find that it’s not just high-risk genes, but how children’s bodies respond to their own intestinal microbiota that relates to future diagnoses of type 1 diabetes.